Hematological Malignancies – Blood Cancers

Hematologic malignancies demand specialized in vivo models that accurately reflect disease biology. LIDE offers a unique portfolio of orthotopic patient-derived xenograft (PDOX) models, rapid-response MiniPDX® and IO-FIVE™ assays, and complementary ex vivo platforms to accelerate blood cancer drug development.

Why LIDE for Hematologic Models?

• Variant-Rich PDX BioBank – Access to rare genetic subtypes, drug-resistant lines, and naturally occurring mutations. Almost 50 different blood cancer models available.
• Orthotopic Fidelity – Intrafemoral AML/ALL PDOX models maintain clinical immunophenotype, cytogenetics, and drug sensitivity profiles.
• Translational Integration – In vivo, ex vivo, and multi-omics data combine to guide indication selection, efficacy validation, biomarker discovery, and even patient stratification.

---

PDX & Orthotopic PDOX Models

LIDE offers one of the most comprehensive hematological malignancy model portfolios in the preclinical CRO space, spanning ALL, AML, lymphoma subtypes, and multiple myeloma. Our models are clinically annotated, genetically characterized, and available in both subcutaneous and orthotopic (intrafemoral) formats, enabling researchers to select the most relevant system for their drug’s mechanism of action.

Legend:
✔ = Available | N/A = Not Applicable / Not Established
s.c. = subcutaneous | i.f. = intrafemoral (orthotopic)

---

Orthotopic CDX Models for Hematology

When patient tissue isn’t available or preferred, LIDE provides well-characterized orthotopic CDX models across multiple hematological malignancies.

---

Applications:

• Checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
• Antibody–drug conjugates
• Bispecific antibodies
• CAR-T and NK-cell therapies
• Combination IO regimens